130 related articles for article (PubMed ID: 2122919)
1. Effects of therapeutic doses of heparin on thrombolysis with tissue-type plasminogen activator in rabbits.
Agnelli G; Pascucci C; Cosmi B; Nenci GG
Blood; 1990 Nov; 76(10):2030-6. PubMed ID: 2122919
[TBL] [Abstract][Full Text] [Related]
2. Affects of hirudin and heparin on the binding of new fibrin to the thrombus in t-PA treated rabbits.
Agnelli G; Pascucci C; Cosmi B; Nenci GG
Thromb Haemost; 1991 Nov; 66(5):592-7. PubMed ID: 1839474
[TBL] [Abstract][Full Text] [Related]
3. Bolus thrombolysis in venous thromboembolism.
Agnelli G; Parise P
Chest; 1992 Apr; 101(4 Suppl):172S-182S. PubMed ID: 1555482
[TBL] [Abstract][Full Text] [Related]
4. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
[TBL] [Abstract][Full Text] [Related]
5. Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparin.
Agnelli G; Renga C; Weitz JI; Nenci GG; Hirsh J
Blood; 1992 Aug; 80(4):960-5. PubMed ID: 1498336
[TBL] [Abstract][Full Text] [Related]
6. The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits.
Agnelli G; Pascucci C; Cosmi B; Nenci GG
Thromb Haemost; 1990 Apr; 63(2):204-7. PubMed ID: 2363121
[TBL] [Abstract][Full Text] [Related]
7. The effect of thrombin inhibitors on tissue plasminogen activator induced thrombolysis in a rat model.
Klement P; Borm A; Hirsh J; Maraganore J; Wilson G; Weitz J
Thromb Haemost; 1992 Jul; 68(1):64-8. PubMed ID: 1514174
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of recombinant tissue-type plasminogen activator thrombolysis with a selective factor Xa inhibitor derived from the leech Hirudo medicinalis: comparison with heparin and hirudin in a rabbit thrombosis model.
Kornowski R; Eldor A; Werber MM; Ezov N; Zwang E; Nimrod A; Chernine A; Finkelstein A; Panet A; Laniado S; Keren G
Coron Artery Dis; 1996 Dec; 7(12):903-9. PubMed ID: 9116933
[TBL] [Abstract][Full Text] [Related]
9. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
[TBL] [Abstract][Full Text] [Related]
10. Low molecular weight heparin (Fragmin) prevents early reocclusion following femoral artery thrombolysis with rt-PA in rabbits.
Kornowski R; Glikson M; Hasdai D; Chernine A; Ohad D; Battler A
Eur Heart J; 1994 Apr; 15(4):541-6. PubMed ID: 8070483
[TBL] [Abstract][Full Text] [Related]
11. D-Phe-Pro-Arg-chloromethylketone: its potential use in inhibiting the formation of in vitro artifacts in blood collected during tissue-type plasminogen activator thrombolytic therapy.
Mohler MA; Refino CJ; Chen SA; Chen AB; Hotchkiss AJ
Thromb Haemost; 1986 Oct; 56(2):160-4. PubMed ID: 2433785
[TBL] [Abstract][Full Text] [Related]
12. Reocclusion after thrombolysis: a problem solved by hirudin?
Rübsamen K; Eschenfelder V
Blood Coagul Fibrinolysis; 1991 Feb; 2(1):97-100. PubMed ID: 1773004
[TBL] [Abstract][Full Text] [Related]
13. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis.
Sitko GR; Ramjit DR; Stabilito II; Lehman D; Lynch JJ; Vlasuk GP
Circulation; 1992 Feb; 85(2):805-15. PubMed ID: 1735171
[TBL] [Abstract][Full Text] [Related]
14. SSR182289A enhances thrombolysis induced by fibrinolytic agents in rabbit models of venous and arterial thrombosis.
Visconte C; Sainte-Marie M; Lorrain J; Millet L; O'Connor SE; Schaeffer P; Herbert JM
J Thromb Haemost; 2004 Apr; 2(4):629-36. PubMed ID: 15102019
[TBL] [Abstract][Full Text] [Related]
15. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin.
Mruk JS; Zoldhelyi P; Webster MW; Heras M; Grill DE; Holmes DR; Fuster V; Chesebro JH
Circulation; 1996 Feb; 93(4):792-9. PubMed ID: 8641009
[TBL] [Abstract][Full Text] [Related]
16. Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis.
Rebello SS; Bentley RG; Morgan SR; Kasiewski CJ; Chu V; Perrone MH; Leadley RJ
Br J Pharmacol; 2001 Aug; 133(7):1190-8. PubMed ID: 11487531
[TBL] [Abstract][Full Text] [Related]
17. In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator.
Jang IK; Gold HK; Leinbach RC; Fallon JT; Collen D
Circ Res; 1990 Dec; 67(6):1552-61. PubMed ID: 2123135
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin.
Cercek B; Lew AS; Hod H; Yano J; Reddy NK; Ganz W
Circulation; 1986 Sep; 74(3):583-7. PubMed ID: 3091287
[TBL] [Abstract][Full Text] [Related]
19. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration.
Collen D; Stassen JM; Verstraete M
J Clin Invest; 1983 Feb; 71(2):368-76. PubMed ID: 6681615
[TBL] [Abstract][Full Text] [Related]
20. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.
Collen D; Stassen JM; Yasuda T; Refino C; Paoni N; Keyt B; Roskams T; Guerrero JL; Lijnen HR; Gold HK
Thromb Haemost; 1994 Jul; 72(1):98-104. PubMed ID: 7974384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]